University Of Notre Dame Du Lac Ascendis Pharma A/S Transaction History

University Of Notre Dame Du Lac

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$110.87 - $156.01 $863,344 - $1.21 Million	-7,787 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$97.01 - $145.11 $75,279 - $112,605	-776 Reduced 9.06%	7,787 $877,000
Q4 2019 Feb 14, 2020	BUY	$91.45 - $139.12 $73,983 - $112,548	809 Added 10.43%	8,563 $1.19 Million
Q3 2019 Nov 13, 2019	SELL	$95.8 - $118.9 $2.14 Million - $2.66 Million	-22,380 Reduced 74.27%	7,754 $747,000
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $693,965 - $855,811	-6,479 Reduced 17.7%	30,134 $3.47 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $180,483 - $377,490	-2,904 Reduced 7.35%	36,613 $4.31 Million
Q4 2018 Feb 13, 2019	SELL	$55.16 - $69.67 $74,686 - $94,333	-1,354 Reduced 3.31%	39,517 $2.48 Million
Q3 2018 Nov 13, 2018	SELL	$63.77 - $76.28 $83,474 - $99,850	-1,309 Reduced 3.1%	40,871 $2.9 Million
Q2 2018 Aug 14, 2018	SELL	$58.55 - $73.92 $340,585 - $429,992	-5,817 Reduced 12.12%	42,180 $2.81 Million
Q1 2018 May 15, 2018	SELL	$38.98 - $68.04 $1 Million - $1.75 Million	-25,774 Reduced 34.94%	47,997 $3.14 Million
Q4 2017 Feb 13, 2018	BUY	$31.98 - $40.38 $2.36 Million - $2.98 Million	73,771	73,771 $2.96 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.